145 related articles for article (PubMed ID: 2242019)
1. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10.
Bai RL; Pettit GR; Hamel E
Biochem Pharmacol; 1990 Oct; 40(8):1859-64. PubMed ID: 2242019
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
[TBL] [Abstract][Full Text] [Related]
3. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
Bai R; Friedman SJ; Pettit GR; Hamel E
Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
[TBL] [Abstract][Full Text] [Related]
4. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
Bai R; Pettit GR; Hamel E
Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
[TBL] [Abstract][Full Text] [Related]
5. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic agents 365. Dolastatin 10 SAR probes.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Boyd MR; Hamel E; Pettit RK; Hogan F; Bai R; Chapuis JC; McAllister SC; Schmidt JM
Anticancer Drug Des; 1998 Jun; 13(4):243-77. PubMed ID: 9627667
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
Beckwith M; Urba WJ; Longo DL
J Natl Cancer Inst; 1993 Mar; 85(6):483-8. PubMed ID: 8445676
[TBL] [Abstract][Full Text] [Related]
10. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E
Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226
[TBL] [Abstract][Full Text] [Related]
11. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
[TBL] [Abstract][Full Text] [Related]
12. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
[TBL] [Abstract][Full Text] [Related]
13. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
Bai R; Durso NA; Sackett DL; Hamel E
Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
[TBL] [Abstract][Full Text] [Related]
14. Antineoplastic agents 360. Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications.
Pettit GR; Flahive EJ; Boyd MR; Bai R; Hamel E; Pettit RK; Schmidt JM
Anticancer Drug Des; 1998 Jan; 13(1):47-66. PubMed ID: 9474242
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and X-ray crystal structure of the dolabellaauricularia peptide dolastatin 18.
Pettit GR; Hogan F; Herald DL
J Org Chem; 2004 Jun; 69(12):4019-22. PubMed ID: 15176826
[TBL] [Abstract][Full Text] [Related]
16. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS
Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845
[TBL] [Abstract][Full Text] [Related]
18. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding.
Li Y; Kobayashi H; Hashimoto Y; Shirai R; Hirata A; Hayashi K; Hamada Y; Shioiri T; Iwasaki S
Chem Biol Interact; 1994 Dec; 93(3):175-83. PubMed ID: 7923438
[TBL] [Abstract][Full Text] [Related]
19. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
Cruz-Monserrate Z; Vervoort HC; Bai R; Newman DJ; Howell SB; Los G; Mullaney JT; Williams MD; Pettit GR; Fenical W; Hamel E
Mol Pharmacol; 2003 Jun; 63(6):1273-80. PubMed ID: 12761336
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tubulin polymerization by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin 10.
Edler MC; Fernandez AM; Lassota P; Ireland CM; Barrows LR
Biochem Pharmacol; 2002 Feb; 63(4):707-15. PubMed ID: 11992639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
